St. Louis, MO – Cofactor Genomics, Inc. has announced the publication of results from their PREDAPT clinical trial (NCT04510129) in the Journal for ImmunoTherapy of Cancer, demonstrating the clinical validity and utility of OncoPrism-HNSCC in predicting response to immune checkpoint inhibitors (ICI) in head and neck squamous cell carcinoma (HNSCC).
Enhanced Predictive Accuracy
The multicenter study revealed that OncoPrism-HNSCC offers a 300% improvement in specificity over PD-L1 CPS and a 400% improvement in sensitivity over Tumor Mutational Burden (TMB) in predicting patient benefit from ICI. These improvements address the shortcomings of PD-L1 and TMB, which have led to overtreatment and poorer outcomes for HNSCC patients.
Clinical Impact and Expert Opinion
Dr. Douglas Adkins, a head and neck oncologist and Professor of Medicine at Washington University School of Medicine, stated, "The OncoPrism assay provides a new and important tool to help clinicians decide about treatment options for their patients with recurrent or metastatic head and neck cancer." OncoPrism-HNSCC aims to bridge the precision medicine gap by providing clinicians with data to make better-informed treatment decisions.
Study Details and Findings
The study, titled "Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study," demonstrated that OncoPrism-HNSCC significantly predicted disease control and progression-free survival in patients from 17 healthcare systems treated with ICI, either as a single agent or in combination with chemotherapy. The study also suggests potential health economic benefits by optimizing personalized treatment strategies.
RNA-Based Technology
Dr. Eric Duncavage, Medical Director at Cofactor Genomics, explained, "This study underscores how new molecular technologies continue to drive precision medicine. Cofactor’s Health Expression Models represent an emerging category of diagnostic technologies that use RNA expression paired with machine learning to directly measure the body’s immune response to cancer...Cofactor’s precision diagnostics enable precision medicine where other technologies lack sufficient diagnostic specificity."
